Specialties

A study based on the Look AHEAD trial examined how weight loss and physical activity impact the risk of HF, MI, and T2DM.

Study finds patients with a higher degree of retinopathy severity had worse cardiovascular outcomes. 

A cohort study on the risk of major adverse kidney events for new patients initiated on empagliflozin versus other non-SGLT2I antihyperglycemics.

A patient, 62 years of age, with type 2 diabetes, obesity, and an intellectual disability disorder, had been a patient at our clinic for over ten years. Treatment included metformin and insulin. He met regularly with his endocrinologist and diabetes educator. He often spoke about wanting to lose weight....

Less than 20% of children with type 1 diabetes attain the target glycated hemoglobin level of less than 7% recommended by the American Diabetes Association.

The first study conducted on this device that explores the effectiveness and safety parameters. 

There is a potential role in using dapagliflozin in patients with CKD. 

How physical activity and dietary intervention affect fasting insulin levels and insulin resistance in children. 

Although not the most prevalent comorbid condition in patients with T2DM, heart failure was the most fatal in a 17-year long nationwide real-life cohort study. 

How triple therapy can lead to optimal cardiovascular and renal protection.